Sign in
4

Changes in Ownership

CRISPR Therapeutics AG Filed Acc 0000899243-17-013806

Chief Executive Officer sold 50,000 shares at an average $16.26 ($812,859)

  • Chief Executive Officer acquired 50,000 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Novak Rodger · Chief Executive Officer

Table I: Non-derivative

4 lines
Date Transaction Shares Price Value Owned after D/I
2017-05-16 Exercise or conversion : show line 1 in the form +24,077 $1.81 $43,579 1,239,082 D
2017-05-16 Sale : show line 2 in the form −24,077 $16.50 $397,283 1,215,005 D
2017-05-17 Exercise or conversion : show line 3 in the form +25,923 $1.81 $46,921 1,240,928 D
2017-05-17 Sale : show line 4 in the form −25,923 $16.03 $415,577 1,215,005 D
Open-market sales · 50,000 sh · avg $16.26 · $812,859

Table II: Derivative

2 lines
Date Transaction Shares Exercise Expires Underlying Owned after D/I
2017-05-16 Exercise or conversion : show line 5 in the form Stock Options (Right to Buy) −24,077 $1.81 2025-09-10 24,077 144,016 D
2017-05-17 Exercise or conversion : show line 6 in the form Stock Options (Right to Buy) −25,923 $1.81 2025-09-10 25,923 118,093 D
Loading xslF345X03/doc4.xml…